Skip to main content
T-Therapeutics  I  About

Christopher Herring

Vice President of Biology & Safety

Chris serves as the Vice President of Biology and Safety at T-Therapeutics, bringing extensive experience in the cell and gene therapy space.

Prior to T-Therapeutics, Chris was Senior Director and then VP of Discovery Research at Adaptimmune, leading the early discovery pipeline from mass spectrometry, target and TCR discovery through to next-generation T cell engineering teams.

Before that he led groups and projects in GSK’s Cell and Gene Therapy Discovery Research Group working on CAR-T, TCR-T and AAV vectored antibody projects.

He has extensive experience from GSK and Domantis in developing half-life extended biologics, as well as bispecific and other novel antibody-based formats including immunocytokines.

Chris holds a PhD in Oncology from the Paterson Institute for Cancer Research (University of Manchester) and a BSc(Hons) from the University of Surrey.

T-Therapeutics
Suite 1
Riverside 3
Granta Park
Cambridge
CB21 6AD